|
**Overview**: Immune Deficiency 5 Panel**Introduction**: The Immune Deficiency 5 Panel is a diagnostic tool designed for comprehensive immune status assessment using whole blood samples. In India, combined immunodeficiencies and HIV cause severe recurrent infections, with extended subset analysis (CD3/CD4/CD8/CD19/NK) essential for classifying defects. High morbidity from under-testing in rural/low-SES children with persistent infections, limited flow labs, delayed IVIG/HSCT leading to mortality. Per immunology practices aligned with ICMR and Indian Society for Primary Immune Deficiency guidelines, the test employs flow cytometry for CD3, CD4, CD8, CD19, and NK cells over 1-2 days with high accuracy, valuable for PID screening and HIV monitoring. This diagnostic falls under immune profiling and targets patients with severe/recurrent infections or family PID history, addressing accurate detection to guide replacement therapy or transplant. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise immune subset evaluation and reducing infection mortality. Its whole blood-based approach ensures reliable enumeration.**Other Names**: Imm Def 5 Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: Comprehensive subset panel; in India, used in PID centers.**Purpose**: The test assesses 5 parameters including CD3 count to guide immune deficiency assessment, evaluate major subsets, inform therapy.**Test Parameters**: 1. CD3 Count, 2. CD4 Count, 3. CD8 Count, 4. CD19 Count, 5. NK Cells.**Pretest Condition**: No fasting required; patients should report recurrent infections.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow).**Medical History**: Patients should provide details on infection pattern, growth, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed immunodeficiency including mortality, benefits of profiling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal subsets indicate specific immunodeficiency, necessitating specialist input.**Specialist Consultation**: Immunologists should be consulted for management.**Additional Supporting Tests**: Ig levels, genetic testing for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, PID Studies India 2023. |
